Form 8-K BIO-RAD LABORATORIES, For: May 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
This stock offers one of the most favorable long-term risk/rewards in biotech: RBC
May 8, 2024 4:30 PM EDTRBC Capital analysts highlighted one stock they believe has a favorable risk/reward in a note Wednesday.
The bank continues to view Bio-Rad Labs (NYSE: BIO) as one of the most compelling long-term investment opportunities in its coverage universe, emphasizing a favorable risk/reward profile.
Despite a 25%... More
Bio-Rad Labs (BIO) PT Lowered to $414 at RBC Capital
May 8, 2024 6:22 AM EDTRBC Capital analyst Conor McNamara lowered the price target on Bio-Rad Labs (NYSE: BIO) to $414.00 (from $420.00) while maintaining a Outperform rating.
The analyst comments "We continue to view BIO as one of the most favorable long-term risk/reward names under coverage; though... More
